Substance specific to human PD-1

• US 7,563,869 B2
• Filed: 01/22/2004
• Issued: 07/21/2009
• Est. Priority Date: 01/23/2003
• Status: Active Grant

• Current Assignee: ONO Pharmaceutical Company Limited, Tasuku Honjo
• Original Assignee: ONO Pharmaceutical Company Limited, Tasuku Honjo
• Inventors: Shibayama, Shiro, Yoshida, Takao, Miyamoto, Masakazu, Takeda, Kazuhiko, Honjo, Tasuku, Matsuo, Masayoshi
• Primary Examiner(s): Ouspenski; Ilia
• Application Number:
  US10/543,323
• Publication Number:
  US 20080025979A1
• Time in Patent Office: 2,007 Days
• Field of Search: None
• US Class Current: 530/350
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 16/2803 : against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2809 : against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2818 : against CD28 or CD152
• CPC Class Codes: C07K 2317/31 : multispecific
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/73 : Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Claims

1. A substantially pure polypeptide selected from the group consisting of (i) to (iii):

(i) a polypeptide comprising the amino acid sequence of SEQ ID NO;

2;

(ii) a polypeptide comprising the amino acid sequence of SEQ ID NO;

4;

(iii) a polypeptide comprising the amino acid sequence of SEQ ID NO;

11.

2. A polypeptide complex comprising the polypeptides (i) and (ii) according to claim 1, which can bind to human PD-1 together.

3. The substantially pure polypeptide according to claim 1, wherein the polypeptide (iii) is a bispecific antibody comprising an antibody against human PD-1, an antibody against human T or B cell receptor complex, and a linker.

4. A bispecific antibody, wherein the following parts are linked by peptide linkers in the following order, respectively:

(a) a polypeptide comprising the amino acid sequence of SEQ ID NO;

2;

(b) a polypeptide comprising the amino acid sequence of SEQ ID NO;

8;

(c) a polypeptide comprising the amino acid sequence of SEQ ID NO;

6, and

(d) a polypeptide comprising the amino acid sequence of SEQ ID NO;

4,

so that said parts (a) and (d) can bind to human PD-1 together and said parts (c) and (b) can bind to human TCR complex together.